Alexander Krakovsky, MD
Pain Management · la Jolla, CANPI 1023096443
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 46 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Collegium Pharmaceutical, Inc. at 24.1% of the total. Reporting peaked in 2019 at $332 and has fallen 95.7% since, to $14 in 2025.
Across 46 payments — averaging $20.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Collegium Pharmaceutical, Inc.$225
- Boston Scientific$200
- Pfizer$135
- GRT US Holding, Inc.$111
- Scilex Pharmaceuticals Inc.$37
- Lilly USA, LLC$36
- plus $191 from 9 others
What the payments were for
- Food & beverage$935100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 13 | $225 |
| Boston Scientific | 8 | $200 |
| Pfizer | 7 | $135 |
| GRT US Holding, Inc. | 4 | $111 |
| Scilex Pharmaceuticals Inc. | 2 | $37 |
| Lilly USA, LLC | 2 | $36 |
| Medtronic | 1 | $28 |
| Abbott | 2 | $28 |
| Amgen | 1 | $25 |
| Biohaven Pharmaceuticals, Inc. | 1 | $24 |
| AbbVie | 1 | $21 |
| Vertical Pharmaceuticals, LLC | 1 | $18 |
| Hikma Pharmaceuticals USA | 1 | $18 |
| Kaleo, Inc. | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$935 in reported general payments places this provider in the 85th percentile of 26 pain management providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PercocetOxycodone Hcl/Acetaminophen | 14 | $42,452 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 64 | $1,507 |
| Lidocaine | 14 | $1,321 |
| Oxycodone Hcl | 21 | $294 |
| Hydromorphone Hcl | 13 | $218 |
| Tizanidine Hcl | 48 | $153 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 13 | $101 |
| Tramadol Hcl | 19 | $89 |
| Gabapentin | 17 | $76 |
Paid to pharmacies, not to this prescriber.
Other pain management in la Jolla
- George PerdikisRidgecrest$3K
- Timothy MansouriFolsom$3K
- Doanh NguyenWestminster$2K
- Anthony TranLos Angeles$454
- Kellie BinderOrange$315
- Nimish ShahHawaiian Gardens$292
- Jennifer ZubickPalmdale$291
- Carolyn HiranoLos Gatos$121
- Peter SchmidtStanford$0
- Sean MackeyStanford$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.